bendamustine hydrochloride

FDA Drug Profile — Bendeka, BENDAMUSTINE HYDROCHLORIDE, bendamustine hydrochloride, BELRAPZO

bendamustine hydrochloride is listed in the FDA National Drug Code directory with 8 NDC codes, marketed under brand names including Bendeka, BENDAMUSTINE HYDROCHLORIDE, bendamustine hydrochloride. Available dosage forms: injection, solution, injection, injection, powder, lyophilized, for solution, powder.

Drug details

Generic Name
bendamustine hydrochloride
Brand Names
Bendeka, BENDAMUSTINE HYDROCHLORIDE, bendamustine hydrochloride, BELRAPZO
Application Number
NDA208194
Sponsor
Teva Pharmaceuticals USA, Inc.
NDC Codes
8
Dosage Forms
INJECTION, SOLUTION, INJECTION, INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION, POWDER
Routes
INTRAVENOUS
Active Ingredients
BENDAMUSTINE HYDROCHLORIDE

Indications and Usage

1 INDICATIONS AND USAGE Non-Hodgkin Lymphoma (NHL) Bendamustine hydrochloride injection is indicated for the treatment of adult patients with indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine hydrochloride injection is an alkylating drug indicated for treatment of adult patients with: • Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. ( 1 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.